-
Mashup Score: 7Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial - 9 month(s) ago
Benralizumab treatment induced histological remission, as defined by absence of tissue eosinophilia, in most patients with eosinophilic gastritis. However, the persistence of histological, endoscopic, and other features of the disease suggest a co-existing, eosinophil-independent pathogenic mechanism and the need for broader targeting of type 2 immunity.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 2Recent Advances in the Treatment of Eosinophilic Esophagitis - 9 month(s) ago
Eosinophilic esophagitis is an increasingly common inflammatory allergic disease of the esophagus characterized by esophageal eosinophilia and symptoms of esophageal dysfunction. The therapeutic landscape has rapidly evolved for this emerging type 2 inflammatory disorder. We review traditional therapies including updates and expert opinions in addition to promising therapies on the horizon and the history of therapies that failed to meet end points and highlight knowledge gaps for future investigations.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma - 1 year(s) ago
Comorbidities in severe asthma are common and contribute to disease burden. The severe asthma phenotype and treatment response can be impacted by comorbid conditions. Real-world data on the use of mepolizumab in severe eosinophilic asthma (SEA) in the presence of comorbidities are needed to inform clinical practice.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Identification of EPX variants in Human Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) - 1 year(s) ago
Clémence David, MD ∗Author Footnotes∗ These authors contributed equally to this work.Clémence DavidFootnotes∗ These authors contributed equally to this work.AffiliationsService de Médecine Interne, Hôpital Cochin, Paris, FranceCentre de Référence National des maladies Auto-Immunes et Systémiques Rares, Hôpital Cochin, Paris, FranceYamina Hamel, PhD ∗Author Footnotes∗ These authors contributed…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1Multifocal bronchial stenosis and extensive lobar atelectasis as a rare radiologic feature of severe eosinophilic asthma - 1 year(s) ago
Bronchial abnormalities on high-resolution computed tomography (CT) are frequent but heterogeneous in severe asthma,1 with airway wall thickening, diffuse airway narrowing, or, conversely, mild bronchiectasia and mucus pluggings being the most frequently observed.2 Focal bronchial stenosis has also been described.3 Although some degree of air trapping is frequently observed on expiratory CT, lung…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1
Instructions for category 1 Continuing Medical Education credit™The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Test ID no.: jaip260Contact hours: 1.00Expiration date: December 31, 2023AMA PRA Category 1 Credit™ can be earned by reading the text material…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
The first report of food allergy desensitization was in 1908, at least a few years before the first published description of a diagnostic test for food allergy. It has taken almost 100 years for food allergy to move from passive management of avoidance to a more proactive approach including prevention and treatment. In parallel, this has been matched by recognition of eosinophil gastrointestinal…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Targeting interleukin-5/5R for the treatment of idiopathic chronic eosinophilic pneumonia - 1 year(s) ago
Article InfoPublication HistoryAccepted: December 17, 2022Received in revised form: November 26, 2022Received: September 5, 2022Publication stageIn Press Journal Pre-ProofFootnotesConflict of interest: CT: grants and consulting fees from GSK, Novartis, Sanofi and AstraZeneca, outside the submitted work; LG reports grants,…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Comorbidities modify the phenotype but not the treatment effectiveness to mepolizumab in severe eosinophilic asthma - 1 year(s) ago
Comorbidities in severe asthma are common and contribute to disease burden. The severe asthma phenotype and treatment response can be impacted by comorbid conditions. Real-world data on the use of mepolizumab in severe eosinophilic asthma (SEA) in the presence of comorbidities is needed to inform clinical practice.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3
The first report of food allergy desensitization was in 1908, at least a few years before the first published description of a diagnostic test for food allergy. It has taken almost 100 years for food allergy to move from passive management of avoidance to a more proactive approach including prevention and treatment. In parallel, this has been matched by recognition of eosinophil gastrointestinal…
Categories: Allergy-Immunology, Latest HeadlinesTweet
On our September issue cover: a phase 2 trial of the eosinophil-depleting antibody benralizumab for #eosinophilic #gastritis has implications for how we understand the pathogenesis of the disease @RothenbergLab https://t.co/gjVkhsikVS #GITwitter https://t.co/CjJHqT0NGX